| Jun 24 |
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
|
| Jun 15 |
ALS therapy market seen increasing to nearly $1.3B by 2029
|
| Jun 7 |
Why Is Prothena (PRTA) Down 1.5% Since Last Earnings Report?
|
| Jun 7 |
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
|
| Jun 6 |
Denali: Cash, Big Pharma Partnerships And High Potential For MPS-II Do Not Warrant A Buy
|
| Jun 6 |
Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?
|
| Jun 4 |
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
|
| Jun 3 |
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
|
